Rising Insulin Therapy Demand by 2030: Why Many Patients Will Go Without Essential Treatment

Concerns and Insights on Diabetes Treatment Options

Overview of Diabetes Prevalence

Recent studies highlight the increasing concerns surrounding the treatment options for individuals with type 1 and type 2 diabetes. This condition affects millions globally, and its prevalence continues to rise. Currently, the total amount of insulin required for diabetes management worldwide remains uncertain.

Study Objective

A recent publication in The Lancet Diabetes & Endocrinology journal investigates the growing population of diabetes patients and their future treatment possibilities. The researchers aimed to estimate the global use of insulin for type 2 diabetes across various countries from 2018 to 2030. They also explored the potential impact of modified insulin treatments on overall insulin usage and related health complications.

Growing Need for Insulin Therapy

Insulin’s Role in Diabetes Management

Insulin is primarily used for treating type 1 diabetes, though a subset of individuals with type 2 diabetes also benefits from insulin therapy. Effective insulin treatment can significantly lower the risks of serious complications, including blindness, amputations, kidney failure, and strokes. With increasing life expectancy among those with type 2 diabetes, there is an urgent need to develop a comprehensive plan to address the rising global demand for insulin, particularly given that it is produced by only three major manufacturers.

Research Methodology

To estimate the global insulin usage for type 2 diabetes, researchers utilized data from the International Diabetes Federation along with 14 cohort studies, covering 221 countries and territories from 2018 to 2030.

Diabetes Population Projections

Leading Countries in Diabetes Cases

The study projects that the number of individuals with type 2 diabetes will increase from approximately 405.6 million in 2018 to 510.8 million by 2030. A significant concentration of this population is found in three countries: China, India, and the USA. In 2018, China accounted for 111.9 million, India for 72.5 million, and the USA for 29.3 million diabetes cases.

Future Projections

By 2030, China is expected to remain the country with the highest number of type 2 diabetes cases, with estimates around 130.2 million, followed by India at 98.0 million and the USA at 31.8 million. The study also anticipates an increase in insulin usage, forecasting a rise from 516.1 million 1000-unit vials to 633.7 million vials annually between 2018 and 2030.

Regional Insights

Asia is projected to have the highest number of insulin users, reaching 321.6 million by 2030. Conversely, the diagnosis rate and insulin usage for type 2 diabetes in Africa are expected to be lower compared to the Americas, which will see higher rates of both diagnoses and insulin usage. If insulin becomes widely accessible, the African region could see a sevenfold increase in insulin therapy usage. Additionally, the number of insulin treatments in Asia could grow from 21.1 million to 47.6 million. The study also suggests that raising the glucose target level to 8% could decrease the global requirement for insulin treatment and lower blood sugar levels by 44%.

Challenges in Insulin Accessibility

Manufacturing and Cost Issues

A significant barrier preventing many individuals with type 1 and type 2 diabetes from receiving insulin therapy is the fact that it is manufactured by only three major companies. This limited availability impacts accessibility for those in need. Furthermore, the high cost of insulin remains a substantial challenge, making it unaffordable for many patients requiring treatment.

Study Limitations

The researchers acknowledged several limitations in their study. One major limitation is that projections for type 2 diabetes prevalence did not account for changes in dietary habits and physical activity over time, which can affect accuracy. Additionally, the methodologies were derived from U.S. data, assuming uniformity in sex, age, blood pressure, and blood sugar levels across different countries.

Conclusion

This study emphasizes the necessity for countries to develop strategies to address the growing demand for insulin in treating type 2 diabetes. It provides valuable insights into the potential impact of increased insulin usage and highlights the need for improved accessibility and affordability of diabetes treatments.

References

Basu, S. (2018). The Lancet Diabetes & Endocrinology: Global study predicts more than 20 percent rise in insulin use by 2030. The Lancet Diabetes & Endocrinology. Retrieved from https://www.eurekalert.org/pub_releases/2018-11/tl-tld111918.php
Basu, S., Yudkin, J.S., Kehlenbrink, S., Davies, J.I., Wild, S.H., Lipska, K.J., Sussman, J.B., Beran, D. (2018). Estimation of global insulin use for type 2 diabetes, 2018–30: a microsimulation analysis. The Lancet Diabetes & Endocrinology. Retrieved from http://dx.doi.org/10.1016/S2213-8587(18)30303-6